Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 8357/S. 4325, 6PPD Task Force Act.
H.R. 8357/S. 4325, 6PPD Task Force Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
LANXESS CORPORATION via LANXESS CORPORATION
2026 · third_quarter · Q3
Section 338 tariffs on Canada.
Modernization of Food and Drug Administration's "generally recognized as safe" (GRAS) framework.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Source: Senate LDA
2026 · second_quarter · Q2
H.R. 8357/S. 4325, 6PPD Task Force Act.
Modernization of Food and Drug Administration's "generally recognized as safe" (GRAS) framework.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANXESS CORPORATION via LANXESS CORPORATION
2026 · first_quarter · Q1
Issues related to trade policy and tariffs.
Issues related to trade policy and tariffs.
Issues related to trade policy and tariffs; Toxic Substances Control Act fees reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANXESS CORPORATION via LANXESS CORPORATION
2025 · fourth_quarter · Q4
Issues related to trade policy and tariffs.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
LANXESS CORPORATION via LANXESS CORPORATION
2025 · third_quarter · Q3
Issues related to chemical management.
Issues related to trade policy and miscellaneous tariff bills.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE